TIMP1 is also thought to be a viable target for the treatment of colon cancer since it was shown that it stimulates the growth and invasiveness of right-sided colon cancer cells via the FAK/Akt signaling pathway [55]. Here, AKT1 is linked to colonic neoplasm.